Topical Clonazepam Solution for the Management of Burning Mouth Syndrome: A Retrospective Study

Aims: To evaluate and compare the effectiveness of two concentrations of topical clonazepam solution in improving symptoms of burning mouth syndrome (BMS). Methods: A retrospective chart review was conducted of patients diagnosed with BMS and managed with topical clonazepam solution between 2008 and 2015. A 0.5-mg/mL solution was prescribed until 2012, when this was changed to a 0.1 mg/mL solution. Patients were instructed to swish with 5 mL for 5 minutes and spit two to four times daily. The efficacies of the two concentrations were compared using patient-reported outcome measures at the first follow-up, including the reported percentage of improvement in burning symptoms and the change in burning severity from baseline ranked on an 11-point numeric rating scale (NRS). Response to treatment was compared between the two concentrations using Wilcoxon rank sum test. Results: A total of 57 subjects were included, 32 in the 0.1-mg/mL cohort and 25 in the 0.5-mg/mL cohort, and evaluated at a median follow-up of 7 weeks. The median overall percentage improvement was 32.5% in the 0.1-mg/mL cohort and 75% in the 0.5-mg/mL cohort. The median reduction in NRS score was 0.5 points in the 0.1-mg/mL cohort and 6 points in the 0.5-mg/mL cohort. The use of either outcome measure revealed that the response to treatment with the 0.5-mg/mL solution was superior to that of the 0.1 mg/mL solution (P < .01). Conclusion: These findings suggest that a 0.5-mg/mL topical clonazepam solution is effective in the management of BMS. Future randomized clinical trials are warranted.

BMS; compounded rinse; oral burning; oral dysesthesia; topical treatment

1. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: Overview and patient management. Crit Rev Oral Biol Med 2003;14:275–291.

2. Tammiala-Salonen T, Hiidenkari T, Parvinen T. Burning mouth in a Finnish adult population. Community Dent Oral Epidemiol 1993;21:67–71.

3. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc 1993;124:115–121.

4. Bergdahl M, Bergdahl J. Burning mouth syndrome: Prevalence and associated factors. J Oral Pathol Med 1999;28:350–354.

5. Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis

MD. The prevalence of burning mouth syndrome: A population-based study. Br J Dermatol 2015;172:1654–1656.

6. Grushka M. Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987;63:30–36.

7. Patton LL, Siegel MA, Benoliel R, De Laat A. Management of burning mouth syndrome: Systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(suppl):s39, e1–e13.

8. Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carrassi A. Burning mouth syndrome: A retrospective study investigating spontaneous remission and response to treatments. Oral Dis 2006;12:152–155.

9. Klasser GD, Fischer DJ, Epstein JB. Burning mouth syndrome: Recognition, understanding, and management. Oral Maxillofac Surg Clin North Am 2008;20:255–271.

10. Formaker BK, Mott AE, Frank ME. The effects of topical anesthesia on oral burning in burning mouth syndrome. Ann N Y Acad Sci 1998;855:776–780.

11. Grémeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, Woda A. Effect of lingual nerve block on burning mouth syndrome (stomatodynia): A randomized crossover trial. Pain 2010;149:27–32.

12. Lauria G, Majorana A, Borgna M, et al. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain 2005;115:332–337.

13. Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007;14:864–871.

14. Puhakka A, Forssell H, Soinila S, et al. Peripheral nervous system involvement in primary burning mouth syndrome—Results of a pilot study. Oral Dis 2016;22:338–344.

15. Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed) 1988;296:1243–1246.

16. Schiavone V, Adamo D, Ventrella G, et al. Anxiety, depression, and pain in burning mouth syndrome: First chicken or egg?Headache 2012;52:1019–1025.

17. Amenábar JM, Pawlowski J, Hilgert JB, et al. Anxiety and salivary cortisol levels in patients with burning mouth syndrome: Case-control study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:460–465.

18. Mignogna MD, Pollio A, Fortuna G, et al. Unexplained somatic comorbidities in patients with burning mouth syndrome: A controlled clinical study. J Orofac Pain 2011;25:131–140.

19.

de Moraes M, do Amaral Bezerra BA, da Rocha Neto PC, de Oliveira Soares AC, Pinto LP, de Lisboa Lopes Costa A. Randomized trials for the treatment of burning mouth syndrome: An evidence-based review of the literature. J Oral Pathol Med 2012;41:281–287.

20. Kuten-Shorrer M, Kelley JM, Sonis ST, Treister NS. Placebo effect in burning mouth syndrome: A systematic review. Oral Dis 2014;20:e1–e6.

21. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002;65:615–620.

22. Grushka M, Epstein J, Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:557–561.

23. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: A randomised placebo-controlled study. Pain 2004;108:51–57.

24. Barker KE, Batstone MD, Savage NW. Comparison of treatment modalities in burning mouth syndrome. Aust Dent J 2009; 54:300–305.

25. Rodríguez de Rivera Campillo E, López-López J, Chimenos-Küstner E. Response to topical clonazepam in patients with burning mouth syndrome: A clinical study. Bull Group Int Rech Sci Stomatol Odontol 2010;49:19–29.

26. Amos K, Yeoh SC, Farah CS. Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: A retrospective pilot study. J Orofac Pain 2011;25:125–130.

27. Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope 2012;122:813–816.

28. de Castro LA, Ribeiro-Rotta RF. The effect of clonazepam mouthwash on the symptomatology of burning mouth syndrome: An open pilot study.Pain Med 2014;15:2164–2165.

29. Cui Y, Xu H, Chen FM, et al. Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: A meta-analysis. Oral Dis 2016;22:503–511.

30. Headache Classification Commitee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.

31. Lamey PJ, Lewis MA. Oral medicine in practice: Burning mouth syndrome. Br Dent J 1989;167:197–200.

32. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19.

33. Woda A, Navez ML, Picard P, Grémeau C, Pichard-Leandri

E. A possible therapeutic solution for stomatodynia (burning mouth syndrome). J Orofac Pain 1998;12:272–278.

34. Anholt RR, De Souza EB, Oster-Granite ML, Snyder SH. Peripheral-type benzodiazepine receptors: Autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther 1985;233:517–526.

35. Tan SN, Song E, Dong XD, Somvanshi RK, Cairns BE. Peripheral GABAA receptor activation modulates rat tongue afferent mechanical sensitivity. Arch Oral Biol 2014;59:251–257.

36. Conboy LA, Wasserman RH, Jacobson EE, et al. Investigating placebo effects in irritable bowel syndrome: A novel research design. Contemp Clin Trials 2006;27:123–134.

37. Greene CS, Goddard G, Macaluso GM, Mauro G. Topical review: Placebo responses and therapeutic responses. How are they related? J Orofac Pain 2009;23:93–107.